This is just a glimpse of the GLP-1 trends available to CivicScience clients. Want to see the full picture? Let’s talk.

BioSpace recaps 2024’s top venture capital rounds in biopharma, from Xaira Therapeutics’ blockbuster $1B raise to ...

On Jan. 1, North Dakota became the first state in the country where access to drugs like Wegovy is part of the EHB package. About 55,293 of North Dakota's 784,000 residents had coverage through fully ...

The firm said it struck a three-year licensing deal with a top pharmaceutical company that will use the data to advance GLP-1 receptor agonist research.

Holiday weight gain hits home for many come January. These days, folks making resolutions to slim down and get fit have an ...

Just when you thought there couldn’t be investor appetite for yet another GLP-1-focused obesity biotech, Verdiva Bio has ...

Adverse events were frequent, and most were gastrointestinal-related, including nausea, vomiting, diarrhea, constipation.

The move intensifies an ongoing legal battle, as Novo Nordisk joins its major competitor Eli Lilly in opposing a recent initiative by the Outsourcing Facilities Association to include liraglutide in ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

Clarivate Plc (NYSE:CLVT) a leading global provider of transformative intelligence, today announced the release of the twelfth annual Drugs to Watch™ report, a trusted guide to the therapies poised to ...

Growth stocks are equity shares likely to outperform their peers and the broader market. Here's a list of stocks that contain investment potential to beef up your portfolio.